Sun Pharma Q4 net up 23 percent, beats estimate
MUMBAI (Reuters) - Sun Pharmaceutical Industries(SUN.NS) reported a 23.4 percent rise in quarterly net profit beating market estimates, and India's top drugmaker by market value also announced a bonus share issue.
The Mumbai-based company said consolidated net profit rose to 10.12 billion rupees for the fourth quarter ended March 31, compared with 8.2 billion rupees a year earlier. Sales rose 31.8 percent to 30.71 billion rupees.
Analysts, on an average, had expected the company to post net profit of 9.07 billion rupees on net sales of 29.85 billion rupees, according to Thomson Reuters I/B/E/S.
The company also announced a one-for-one issue of bonus shares.
Shares of Sun Pharma, which has a market value of about $18.81 billion, fell 1.72 percent to 996.25 rupees on Tuesday, while the broader market gained 0.65 percent on the day. The stock has risen nearly 38 percent this year outperforming the benchmark index which has gained about 4 percent.
(Reporting by Kaustubh Kulkarni; Editing by Anand Basu)
- Tweet this
- Share this
- Digg this
Trending On Reuters
India's reform-minded prime minister, Narendra Modi, appears to have passed a major test with a budget that pleased economists and investors with pledges to spend more on modernising India's ageing roads and railways while keeping borrowing in check. Full Article | Full Coverage